Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Aldehyde doai
Reexamination Certificate
1998-07-17
2001-04-17
MacMillan, Keith D. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Aldehyde doai
C514S666000, C514S312000, C514S685000, C514S109000, C514S120000, C514S578000, C514S557000, C514S574000, C514S177000, C514S178000, C514S179000, C514S180000, C514S604000, C514S459000, C514S844000, C514S880000
Reexamination Certificate
active
06218435
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to a method of reducing unwanted hair growth in mammals.
A main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed from various parts of the body essentially for cosmetic reasons. For example, it is generally preferred to have hair on the scalp but not on the face.
Various procedures have been employed to remove unwanted hair, including shaving, electrolysis, depilatory creams or lotions, waxing, plucking, and therapeutic antiandrogens. These conventional procedures generally have drawbacks associated with them. Shaving, for instance, can cause nicks and cuts, and can leave a perception of an increase in the rate of hair regrowth. Shaving also can leave an undesirable stubble. Electrolysis, on the other hand, can keep a treated area free of hair for prolonged periods of time, but can be expensive, painful, and sometimes leaves scarring. Depilatory creams, though very effective, typically are not recommended for frequent use due to their high irritancy potential. Waxing and plucking can cause pain, discomfort, and poor removal of short hair. Finally, antiandrogens—which have been used to treat female hirsutism—can have unwanted side effects.
It has previously been disclosed that the rate and character of hair growth can be altered by applying to the skin inhibitors of certain enzymes. These inhibitors include inhibitors of 5-alpha reductase, ornithine decarboxylase, S-adenosylmethionine decarboxylase, gamma-glutamyl transpeptidase, and transglutaminase. See, for example, Breuer et al., U.S. Pat. No. 4,885,289; Shander, U.S. Pat. No. 4,720,489; Ahluwalia, U.S. Pat. No. 5,095,007; Ahluwalia et al., U.S. Pat. No. 5,096,911; Shander et al., U.S. Pat. No. 5,132,293; and Shander et al., U.S. Pat. No. 5,143,925.
Metabolism of glucose to acetyl-CoA is carried out by a series of enzymes, with some enzymes performing a more regulatory (i.e., rate limiting) role than others. The FIGURE illustrates the metabolic pathway for the conversion of glucose to acetyl-CoA.
REFERENCES:
patent: 3426137 (1969-02-01), Philpitt
patent: 4039669 (1977-08-01), Beyler et al.
patent: 4139638 (1979-02-01), Neri et al.
patent: 4161540 (1979-07-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4269831 (1981-05-01), Ferrari et al.
patent: 4344941 (1982-08-01), Wiechert et al.
patent: 4370315 (1983-01-01), Greff et al.
patent: 4439432 (1984-03-01), Peat
patent: 4508714 (1985-04-01), Cecic et al.
patent: 4517175 (1985-05-01), Iwabuchi et al.
patent: 4720489 (1988-01-01), Shander
patent: 4885289 (1989-12-01), Breuer et al.
patent: 4935231 (1990-06-01), Pigiet
patent: 5015470 (1991-05-01), Gibston et al.
patent: 5095007 (1992-03-01), Ahluwalia
patent: 5096911 (1992-03-01), Ahluwalia et al.
patent: 5132293 (1992-07-01), Shander et al.
patent: 5143925 (1992-09-01), Shander et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5271942 (1993-12-01), Heverhagen
patent: 5300284 (1994-04-01), Wiechers et al.
patent: 5336686 (1994-08-01), Nedelec et al.
patent: 5364885 (1994-11-01), Ahluwalia et al.
patent: 5411991 (1995-05-01), Shander et al.
patent: 5455234 (1995-10-01), Ahluwalia et al.
patent: 5468476 (1995-11-01), Ahluwalia et al.
patent: 5474763 (1995-12-01), Shander et al.
patent: 5554608 (1996-09-01), Henry et al.
patent: 0 413 528 A1 (1991-02-01), None
patent: 0 532 219 A2 (1993-03-01), None
patent: 0 711 541 A1 (1996-05-01), None
patent: 1 458 349 (1976-12-01), None
patent: WO 91/04058 (1991-04-01), None
Sato, “The Hair Cycle and Its Control Mechanism”,Biology and Disease of the Hairpp. 3-13 (1975).
Goos et al., “An Improved Method for Evaluating Antiandrogens”,Arch. Dermatol. Res., 273:333-341 (1982).
Messenger, “The Control of Hair Growth: An Overview”,The Journal of Investigative Dermatology, 101:4S-9S, supplement, (1993).
Simpson et al., “The Effect of Topically Applied Progesterone on Sebum Excretion Rate”,British Journal of Dermatology, 100:687-692 (1979).
Harmon et al., “12-0-Tetradecanoylphorbol-13-Acetate Inhibits Human Hair Follicle Growth and Hair Fiber . . . ”,SID Abstracts, 102:533 (1994).
“Cochlear damage and increased threshold in alphadifluoromethylornithine (DFMO) treated guinea pigs” (abstract only), 1994.
Adachi et al., “Human Hair Follicles: Metabolism and Control Mechanisms”,J. Soc. Cosmet. Chem., 21, 901-924 (Dec. 9, 1970).
Adachi et al., “Glucose metabolism of growing and resting human hair follicles”,American Journal of Physiology, vol. 215, No. 5 (Nov. 1968).
Machado de Domenech et al., “Specificity of Hexokinases Towards Some Uncommon Substrates and Inhibitors”,FEBS Letters, vol. 119, No. 1 (1980).
Johnson et al., “Inhibition of Hexokinase and Protein Kinase Activities of Tumor Cells by a Chloromethyl Ketone Derivative of Lactic Acid”,Biochemistry, vol. 21, No. 12 (1982).
Colombo et al., “Interaction of Inhibitors with Muscle Phosphofructokinase”,The Journal of Biological Chemistry, vol. 250, No. 24, Issue of Dec. 25, pp. 9404-9412 (1975).
McCune et al., “Aurintricarboxylie acid is a potent inhibitor of phosphofructokinase”,Biochem. J., 259, 925-927 (1989).
Mansour et al., “Affinity Labeling of AMP-ADP Sites in Heart Phosphofructokinaseby 5′-p-Fluorosulfonylbenzoyl . . . ”,Biochem. and Biophysical Research Communications, vol. 81, No. 4 (1978).
Avigad et al., “Synthesis of 5-keto-D-Fructose 1,6-Bisphosphate and Some of Its Properties”,Biochimica et Biophysica Acta, 343, 330-340 (1974).
Kuntz et al., “Phosphoglycerate Kinase from Animal Tissue”,Methods in Enzymology, vol. 90, 103-110 (1982).
Liu et al., “Synthesis and Study of (Z)-3-Chlorophosphoenolpyruvate”,Archives of Biochemistry and Biophysics, vol. 277, No. 1, Feb. 15, pp. 143-148 (1990).
Wirsching et al., “(E-3-Cyanophosphoenolpyruvate, a New Inhibitor of Phosphoenolpyruvate-Dependent Enzymes”,Biochemistry, 24, 7602-7606 (1985).
Spring et al., “Studies on Two High-Affinity Enolase Inhibitors. Reaction with Enolases”,Biochemistry, vol. 10, No. 25 (1971).
Rose et al., “Inactivation and Labeling of Triose Phosphate Isomerase and Enolase by Glycidol Phosphate”,The Journal of Biological Chemistry, vol. 244, No. 23, issue of Dec. 10, pp. 6548-6557 (1969).
O'Leary et al., “1-Hydroxycyclopropane Carboxylic Acid Phosphate: A Potent Inhibitor of Enzymes . . . ”,Biochemical and Biophysical Research Communication, vol. 100, No. 3 (1981).
Blaswanger, “Substrate Specificity of the Pyruvate Dehydrogenase Complex fromEscherichia coli”,The Journal of Biological Chemistry, vol. 256, No. 2, issue of Jan. 25, pp. 815-822 (1981).
Furuta et al., “Pyruvate Dehydrogenase Complex from Pigeon Breast Muscle”,Methods in Enzymology, vol. 89, pp. 414-420 (1982).
Waymack et al., “The Effect of Pyruvate Transport Inhibitors on the Regulation of Pyruvate Dehydrogenase in the Perfused Rat Heart”,Archives of Biochemistry and Biophysics, vol. 194, No. 1, pp. 258-264 (1979).
Lowe et al., Bromopyruvate as an Active-Site-Directed Inhibitor of the Pyruvate Dehydrogenase Multienzyme Complex fromEscherichia coli,Biochemistry, 23, 91-97 (1984).
Bisswanger, “Fluoropyruvate: A Potent Inhibitor of the Bacterial and the Mammalian Pyruvate Dehydrogenase Complex”,Biochemical and Biophysical Research Communications, vol. 95, No. 2 (1980).
Coe, “Inhibition of Glycolysis in Ascites Tumor Cells Preincubated with 2-Deoxy-2-Fluoro-D-Glucose”,Biochim. Biophys. Acta, 264, 319-327 (1972).
Taylor et al., “Metabolic and Transport Studies with Deoxyfluoro-monosaccharides”ACS Symposium Series: Biochemistry Involving Carbon-Fluorine Bonds, pp. 99-116 (1975).
Hanson et al., “Inhibition of Phosphofructokinase by Quinone Methide and &agr;-Methylene Lactone Tumor Inhibitors”,Science, vol. 168, pp. 378-380 (1970).
Scopes, “3-Phosphoglycerate Kinase of Baker's Yeast”,Methods in Enzymology, 90:134-138 (1982).
Tielens et al., The Effect of 5-Thioglucose on the Energy Metabolism of Schistosoma Mansoni in Vitro,Biochemical Pharmacology, pp. 3369-3373, Abstract only, Sep. 15, 1985.
PCT Search Report, partial copy, PCT US/96/19
Ahluwalia Gurpreet
Henry James
Shander Douglas
Fish & Richardson P.C.
MacMillan Keith D.
LandOfFree
Reduction of hair growth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reduction of hair growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of hair growth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2466102